Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab in Unresectable Malignant Mesothelioma
NCT02588131Phase 2Unknown
- Sponsor
- NIBIT Foundation
- Start
- Oct 2015
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in malignant mesothelioma, sponsored by NIBIT Foundation. Status: unknown.
02
Drugs
durvalumab
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT02588131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588131.